Literature DB >> 32681365

The effectiveness of conservative interventions for the management of syndromic hypermobility: a systematic literature review.

Shea Palmer1, Indi Davey2, Laura Oliver2, Amara Preece2, Laura Sowerby2, Sophie House2.   

Abstract

INTRODUCTION: 'Syndromic hypermobility' encompasses heritable connective tissue disorders such as hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders which are characterised by excessive joint range of motion and pain. Conservative interventions such as exercise are the cornerstone of management, yet their effectiveness is unclear. AIM: To systematically appraise the effectiveness of conservative management for people with syndromic hypermobility.
METHOD: A systematic online database search was conducted (AMED, BND, CINAHL Plus, MEDLINE, PEDro, PsychINFO and SportDiscus). Potential articles were assessed for eligibility by two researchers against the following criteria: adults and children with a hEDS/HSD diagnosis (or equivalent diagnosis using specific criteria); non-pharmacological or non-surgical interventions; outcomes related to pain, physical function, psychological well-being or quality of life. Controlled trials and cohort studies were included. Critical Appraisal Skills Programme checklists were used to assess methodological quality.
RESULTS: Eleven studies were included, comprising eight controlled trials and three cohort studies. All studies investigated interventions that had exercise as the primary component. Three small controlled studies demonstrated superior effects of conservative management relative to a control group. However, those studies only focused on a single area of the body, only recruited women, and had no long-term follow-up. All studies reported improvements in a wide range of outcomes over time.
CONCLUSION: Controlled trial evidence for the superiority of conservative management over comparators is weak. There is some evidence that people improve over time. Robust randomised controlled trial research of the long-term effectiveness of 'whole-body' (rather than individual joints or body areas) conservative management is required. Key Points • Conservative management is the cornerstone of management of syndromic hypermobility. • The review found that evidence for the effectiveness of conservative management relative to no treatment or other conservative comparators was weak. • However, there was consistent evidence for effectiveness from pre- to post-treatment. • Further robust randomised controlled trial evidence is required.

Entities:  

Keywords:  Conservative treatment; Ehlers-Danlos Syndrome; Hypermobility; Systematic review

Mesh:

Year:  2020        PMID: 32681365      PMCID: PMC7895781          DOI: 10.1007/s10067-020-05284-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  53 in total

1.  Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK).

Authors:  P Beighton; A De Paepe; B Steinmann; P Tsipouras; R J Wenstrup
Journal:  Am J Med Genet       Date:  1998-04-28

2.  Reflection on modern methods: selection bias-a review of recent developments.

Authors:  Claire Infante-Rivard; Alexandre Cusson
Journal:  Int J Epidemiol       Date:  2018-10-01       Impact factor: 7.196

3.  Characterization of the relationship between joint laxity and maternal hormones in pregnancy.

Authors:  Mary L Marnach; Kirk D Ramin; Patrick S Ramsey; Seak-Whan Song; Jacqueline J Stensland; Kai-Nan An
Journal:  Obstet Gynecol       Date:  2003-02       Impact factor: 7.661

4.  Amelioration of symptoms by enhancement of proprioception in patients with joint hypermobility syndrome.

Authors:  William R Ferrell; Nicola Tennant; Roger D Sturrock; Linda Ashton; Gisela Creed; Gillian Brydson; Daniel Rafferty
Journal:  Arthritis Rheum       Date:  2004-10

5.  Multidisciplinary treatment of disability in ehlers-danlos syndrome hypermobility type/hypermobility syndrome: A pilot study using a combination of physical and cognitive-behavioral therapy on 12 women.

Authors:  Trine Bathen; Anett Bjørnødegård Hångmann; Marie Hoff; Liv Øinaes Andersen; Svend Rand-Hendriksen
Journal:  Am J Med Genet A       Date:  2013-08-02       Impact factor: 2.802

6.  Hypermobility and the hypermobility syndrome, part 2: assessment and management of hypermobility syndrome: illustrated via case studies.

Authors:  Jane V Simmonds; Rosemary J Keer
Journal:  Man Ther       Date:  2008-01-24

7.  Are People With Joint Hypermobility Syndrome Slow to Strengthen?

Authors:  May To; Caroline M Alexander
Journal:  Arch Phys Med Rehabil       Date:  2018-12-30       Impact factor: 3.966

Review 8.  Physiotherapy and occupational therapy interventions for people with benign joint hypermobility syndrome: a systematic review of clinical trials.

Authors:  Toby O Smith; Holly Bacon; Emma Jerman; Vicky Easton; Kate Armon; Fiona Poland; Alex J Macgregor
Journal:  Disabil Rehabil       Date:  2013-07-26       Impact factor: 3.033

9.  Factors that can affect the external validity of randomised controlled trials.

Authors:  Peter M Rothwell
Journal:  PLoS Clin Trials       Date:  2006-05

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

View more
  2 in total

Review 1.  Multidisciplinary Approach to Treating Chronic Pain in Patients with Ehlers-Danlos Syndrome: Critically Appraised Topic.

Authors:  Kiley C Whalen; Wilson Crone
Journal:  J Pain Res       Date:  2022-09-13       Impact factor: 2.832

2.  The GoodHope Exercise and Rehabilitation (GEAR) Program for People With Ehlers-Danlos Syndromes and Generalized Hypermobility Spectrum Disorders.

Authors:  Nimish Mittal; Daniel Santa Mina; Stephanie Buryk-Iggers; Laura Lopez-Hernandez; Laura Hussey; Alyssa Franzese; Joel Katz; Camille Laflamme; Laura McGillis; Lianne McLean; Maxim Rachinsky; Dmitry Rozenberg; Maxwell Slepian; Aliza Weinrib; Hance Clarke
Journal:  Front Rehabil Sci       Date:  2021-11-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.